0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Perspective | 
Rita F. Redberg, MD, MSc
JAMA Intern Med. 2013;173(19):1769. doi:10.1001/jamainternmed.2013.9279.

Clinical Observation | 
Nicholas A. Tritos, MD; Pamela Hartzband, MD
Arch Intern Med. 1999;159(13):1495-1498. doi:10.1001/archinte.159.13.1495.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Surgery
Invited Commentary  | 
Borderline Resectable Pancreatic Cancer Answering the Most Important Question First
John A. Windsor, MD, FRACS
JAMA Surgery
Original Investigation  | 
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Alliance for Clinical Trials in Oncology Trial A021101
Matthew H. G. Katz, MD; Qian Shi, PhD; Syed A. Ahmad, MD; et al.
JAMA Surgery
Invited Commentary  | 
How Best to Approach Surgery for Primary Hyperparathyroidism—Can We All Agree?
Julie Ann Sosa, MD, MA
JAMA Surgery
Special Communication  | 
The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism
Scott M. Wilhelm, MD; Tracy S. Wang, MD, MPH; Daniel T. Ruan, MD; et al.